Adenosine Receptor-Mediated Adhesion of Endothelial Progenitors to Cardiac Microvascular Endothelial Cells

Intracoronary delivery of endothelial progenitor cells (EPCs) is an emerging concept for the treatment of cardiovascular disease. Enhancement of EPC adhesion to vascular endothelium could improve cell retention within targeted organs. Because extracellular adenosine is elevated at sites of ischemia and stimulates neovascularization, we examined the potential role of adenosine in augmenting EPC retention to cardiac microvascular endothelium. Stimulation of adenosine receptors in murine embryonic EPCs (eEPCs) and cardiac endothelial cells (cECs) rapidly, within minutes, increased eEPC adhesion to cECs under static and flow conditions. Similarly, adhesion of human adult culture-expanded EPCs to human cECs was increased by stimulation of adenosine receptors. Furthermore, adenosine increased eEPC retention in isolated mouse hearts perfused with eEPCs. We determined that eEPCs and cECs preferentially express functional A1 and A2B adenosine receptor subtypes, respectively, and that both subtypes are involved in the regulation of eEPC adhesion to cECs. We documented that the interaction between P-selectin and its ligand (P-selectin glycoprotein ligand-1) plays a role in adenosine-dependent eEPC adhesion to cECs and that stimulation of adenosine receptors in cECs induces rapid cell surface expression of P-selectin. Our results suggest a role for adenosine in vasculogenesis and its potential use to stimulate engraftment in cell-based therapies.

[1]  I. Biaggioni,et al.  Role of Adenosine Receptors in the Regulation of Angiogenic Factors and Neovascularization in Hypoxia , 2007, Journal of Pharmacology and Experimental Therapeutics.

[2]  F. Fernández‐Avilés,et al.  Bone-marrow-derived cells for cardiac stem cell therapy: safe or still under scrutiny? , 2007, Nature Clinical Practice Cardiovascular Medicine.

[3]  H. Hamm,et al.  Differential regulation of endothelial exocytosis of P-selectin and von Willebrand factor by protease-activated receptors and cAMP. , 2006, Blood.

[4]  Z. Ge,et al.  Adenosine Inhibits Tumor Necrosis Factor-α Release from Mouse Peritoneal Macrophages via A2A and A2B but Not the A3 Adenosine Receptor , 2005, Journal of Pharmacology and Experimental Therapeutics.

[5]  P. Boekstegers,et al.  Embryonic endothelial progenitor cells expressing a broad range of proangiogenic and remodeling factors enhance vascularization and tissue recovery in acute and chronic ischemia , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  T. Asahara,et al.  Endothelial Progenitor Cells Are Rapidly Recruited to Myocardium and Mediate Protective Effect of Ischemic Preconditioning via “Imported” Nitric Oxide Synthase Activity , 2005, Circulation.

[7]  P. Young,et al.  Blood donor white blood cell reduction filters as a source of human peripheral blood–derived endothelial progenitor cells , 2005, Transfusion.

[8]  H. Yee,et al.  Adenosine A(2A) receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis. , 2004, The American journal of pathology.

[9]  B. Fredholm,et al.  Binding of the prototypical adenosine A2A receptor agonist CGS 21680 to the cerebral cortex of adenosine A1 and A2A receptor knockout mice , 2004, British journal of pharmacology.

[10]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[11]  B. Engelhardt,et al.  Multistep Nature of Microvascular Recruitment of Ex Vivo–expanded Embryonic Endothelial Progenitor Cells during Tumor Angiogenesis , 2003, The Journal of experimental medicine.

[12]  R. Frey,et al.  Tumor Necrosis Factor- (cid:1) Induces Early-Onset Endothelial Adhesivity by Protein Kinase C (cid:2) –Dependent Activation of Intercellular Adhesion Molecule-1 , 2022 .

[13]  Winfried Brenner,et al.  Assessment of the Tissue Distribution of Transplanted Human Endothelial Progenitor Cells by Radioactive Labeling , 2003, Circulation.

[14]  I. Biaggioni,et al.  Mast Cell–Mediated Stimulation of Angiogenesis: Cooperative Interaction Between A2B and A3 Adenosine Receptors , 2003, Circulation research.

[15]  T. Voyno-Yasenetskaya,et al.  Differential Expression of Adenosine Receptors in Human Endothelial Cells: Role of A2B Receptors in Angiogenic Factor Regulation , 2002, Circulation research.

[16]  B. Fredholm,et al.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.

[17]  I. Biaggioni,et al.  Inhibition of human mast cell activation with the novel selective adenosine A(2B) receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (IPDX)(2). , 2001, Biochemical pharmacology.

[18]  R. Testa,et al.  Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. , 2000, Circulation.

[19]  K. Jacobson,et al.  Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors. , 1999, Drug design and discovery.

[20]  J. Linden,et al.  Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells. , 1999, Molecular pharmacology.

[21]  J. Folkman,et al.  Isolation and characterization of endothelial progenitor cells from mouse embryos. , 1998, Development.

[22]  I. Biaggioni,et al.  Pharmacological characterization of adenosine A2B receptors: studies in human mast cells co-expressing A2A and A2B adenosine receptor subtypes. , 1998, Biochemical pharmacology.

[23]  B. Fredholm,et al.  Comparative pharmacology of human adenosine receptor subtypes – characterization of stably transfected receptors in CHO cells , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[24]  R. K. Shepherd,et al.  Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. , 1997, The Journal of clinical investigation.

[25]  S. Butcher,et al.  Species differences in brain adenosine A1 receptor pharmacology revealed by use of xanthine and pyrazolopyridine based antagonists , 1997, British journal of pharmacology.

[26]  R. Bolli,et al.  Preconditioning of human myocardium with adenosine during coronary angioplasty. , 1997, Circulation.

[27]  W. Frederiks,et al.  Nitric oxide synthase activity. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[28]  W. Buurman,et al.  Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. , 1996, The American journal of physiology.

[29]  Stefano Manfredini,et al.  Synthesis of new pyrazolo[4,3-e]1,2,4-triazolo[1,5-c] pyrimidine and 1,2,3-triazolo[4,5-e]1,2,4-triazolo[1,5-c] pyrimidine displaying potent and selective activity as A2a adenosine receptor antagonists. , 1994 .

[30]  S. Zahler,et al.  Stimulation of endothelial adenosine A1 receptors enhances adhesion of neutrophils in the intact guinea pig coronary system. , 1994, Cardiovascular research.

[31]  D. Mckenna,et al.  (+-)-N6-endonorbornan-2-yl-9-methyladenine (N-0861) and its enantiomers: selective antagonists of A1-adenosine receptors in guinea pig isolated atria. , 1993, Journal of Pharmacology and Experimental Therapeutics.

[32]  K. Klotz,et al.  2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors. , 1992, Journal of medicinal chemistry.

[33]  S. Abramson,et al.  Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. , 1992, Journal of immunology.

[34]  K. Handa,et al.  Selectin GMP-140 (CD62; PADGEM) binds to sialosyl-Le(a) and sialosyl-Le(x), and sulfated glycans modulate this binding. , 1991, Biochemical and biophysical research communications.

[35]  G. Ghai,et al.  CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity. , 1989, Journal of Pharmacology and Experimental Therapeutics.

[36]  Martin J. Lohse,et al.  8-Cyclopentyl-1,3-dipropylxanthine (DPCPX) — a selective high affinity antagonist radioligand for A1 adenosine receptors , 1987, Naunyn-Schmiedeberg's Archives of Pharmacology.

[37]  G. Lu,et al.  Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes. , 1986, Molecular pharmacology.

[38]  A. Ziada,et al.  The effect of long-term vasodilatation on capillary growth and performance in rabbit heart and skeletal muscle. , 1984, Cardiovascular research.

[39]  R. Berne,et al.  Adenosine in the local regulation of blood flow: a brief overview. , 1983, Federation proceedings.

[40]  D. Haskard,et al.  Conditional immortalization of growth factor-responsive cardiac endothelial cells from H-2K(b)-tsA58 mice. , 2002, American journal of physiology. Cell physiology.

[41]  Syed Jamal Mustafa,et al.  Comparison of the vascular effects of adenosine in isolated mouse heart and aorta. , 2002, American journal of physiology. Heart and circulatory physiology.

[42]  B. Fredholm,et al.  Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[43]  C. Wollheim,et al.  Purine nucleotides induce regulated secretion of von Willebrand factor: involvement of cytosolic Ca2+ and cyclic adenosine monophosphate-dependent signaling in endothelial exocytosis. , 1998, Blood.

[44]  G. Schmid-Schönbein,et al.  Physiology and pathophysiology of leukocyte adhesion , 1995 .

[45]  J. Montani,et al.  Vascular development in chick embryos: a possible role for adenosine. , 1989, The American journal of physiology.

[46]  G. Tornling.  Capillary neoformation in the heart and skeletal muscle during dipyridamole--treatment and exercise. , 1982, Acta pathologica, microbiologica, et immunologica Scandinavica. Supplement.